290 related articles for article (PubMed ID: 31467392)
1. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
Williams NR; Heifets BD; Bentzley BS; Blasey C; Sudheimer KD; Hawkins J; Lyons DM; Schatzberg AF
Mol Psychiatry; 2019 Dec; 24(12):1779-1786. PubMed ID: 31467392
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Williams NR; Heifets BD; Blasey C; Sudheimer K; Pannu J; Pankow H; Hawkins J; Birnbaum J; Lyons DM; Rodriguez CI; Schatzberg AF
Am J Psychiatry; 2018 Dec; 175(12):1205-1215. PubMed ID: 30153752
[TBL] [Abstract][Full Text] [Related]
3. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
Hosanagar A; Schmale A; LeBlanc A
J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
[TBL] [Abstract][Full Text] [Related]
4. Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice.
Zhang F; Hillhouse TM; Anderson PM; Koppenhaver PO; Kegen TN; Manicka SG; Lane JT; Pottanat E; Van Fossen M; Rice R; Porter JH
Pharmacol Biochem Behav; 2021 Sep; 208():173228. PubMed ID: 34224734
[TBL] [Abstract][Full Text] [Related]
5. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
6. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
[TBL] [Abstract][Full Text] [Related]
7. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.
Price RB; Iosifescu DV; Murrough JW; Chang LC; Al Jurdi RK; Iqbal SZ; Soleimani L; Charney DS; Foulkes AL; Mathew SJ
Depress Anxiety; 2014 Apr; 31(4):335-43. PubMed ID: 24668760
[TBL] [Abstract][Full Text] [Related]
8. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
[TBL] [Abstract][Full Text] [Related]
9. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
[TBL] [Abstract][Full Text] [Related]
10. The role of adipokines in the rapid antidepressant effects of ketamine.
Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
[TBL] [Abstract][Full Text] [Related]
11. Disentangling the association of depression on the anti-fatigue effects of ketamine.
Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
[TBL] [Abstract][Full Text] [Related]
12. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
[TBL] [Abstract][Full Text] [Related]
13. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder.
Vande Voort JL; Ballard ED; Luckenbaugh DA; Bernert RA; Richards EM; Niciu MJ; Park LT; Machado-Vieira R; Duncan WC; Zarate CA
J Clin Psychiatry; 2017; 78(8):1068-1074. PubMed ID: 27929610
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
[TBL] [Abstract][Full Text] [Related]
16. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
17. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
[TBL] [Abstract][Full Text] [Related]
19. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
20. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
